» Articles » PMID: 33176299

Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes: COREXH Registry

Overview
Journal Blood Purif
Specialty Hematology
Date 2020 Nov 11
PMID 33176299
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: A new generation of hemodialysis (HD) membranes called medium cut-off (MCO) membranes possesses enhanced capacities for middle molecule clearance, which have been associated with adverse outcomes in this population. These improvements could potentially positively impact patient-reported outcomes (PROs).

Objective: The objective of this study was to evaluate the impact of MCO membranes on PROs in a cohort of HD patients in Colombia.

Methods: This was a prospective, multicenter, observational cohort study of 992 patients from 12 renal clinics in Colombia who were switched from high-flux HD to MCO therapy and observed for 12 months. Changes in Kidney Disease Quality of Life 36-Item Short Form Survey (KDQoL-SF36) domains, Dialysis Symptom Index (DSI), and restless legs syndrome (RLS) 12 months after switching to MCO membranes were compared with time on high-flux membranes. Repeated measures of ANOVA were used to evaluate changes in KDQoL-SF36 scores; severity scoring was used to assess DSI changes over time; Cochran's Q test was used to evaluate changes in frequency of diagnostic criteria of RLS.

Results: During 12 months of follow-up, 3 of 5 KDQoL-SF36 domains improved compared with baseline: symptoms (p < 0.0001), effects of kidney disease (p < 0.0001), and burden of kidney disease (p < 0.001). The proportion of patients diagnosed with RLS significantly decreased from 22.1% at baseline to 10% at 12 months (p < 0.0001). No significant differences in the number of symptoms (DSI, p = 0.1) were observed, although their severity decreased (p = 0.009).

Conclusions: In conventional HD patients, the expanded clearance of large middle molecules with MCO-HD membranes was associated with higher health-related quality of life scores and a decrease in the prevalence of RLS.

Citing Articles

The role of blood purification therapies in the treatment of chronic kidney disease-associated pruritus: a systematic review.

Marcello M, Marturano D, Ronco C, Zanella M Clin Kidney J. 2024; 17(9):sfae266.

PMID: 39319306 PMC: 11420667. DOI: 10.1093/ckj/sfae266.


Psychometric properties of the Kidney Disease Quality of Life short form 36 (KDQOL-36) scale for the assessment of quality of life in Colombian patients with chronic kidney disease on dialysis.

Valderrama-Rios M, Sanchez R, Sanabria M Int Urol Nephrol. 2024; 56(7):2337-2350.

PMID: 38376660 PMC: 11190008. DOI: 10.1007/s11255-024-03940-x.


Intradialytic Tolerance and Recovery Time in Different High-Efficiency Hemodialysis Modalities.

Zakrzewska A, Biedunkiewicz J, Komorniczak M, Jankowska M, Jasiulewicz K, Plonka N J Clin Med. 2024; 13(2).

PMID: 38256460 PMC: 10816973. DOI: 10.3390/jcm13020326.


Medium cut-off dialyzer for middle molecular uremic toxins in AKI and chronic dialysis.

Fiorentino M, La Fergola F, De Rosa S J Nephrol. 2023; 37(1):23-37.

PMID: 37843731 PMC: 10920419. DOI: 10.1007/s40620-023-01771-0.


Response rates in clinical quality registries and databases that collect patient reported outcome measures: a scoping review.

Ruseckaite R, Mudunna C, Caruso M, Ahern S Health Qual Life Outcomes. 2023; 21(1):71.

PMID: 37434146 PMC: 10337187. DOI: 10.1186/s12955-023-02155-5.